US EditionPublished • loading... • Updated
Up 36%, Is Eli Lilly Still a Buy?
Summary by The Motley Fool
1 Articles
1 Articles
Up 36%, Is Eli Lilly Still a Buy?
Key PointsEli Lilly is at the forefront of both diabetes and obesity medications.The pharmaceutical giant has offered strong guidance for the end of 2025.Looking ahead, it seems likely that demand in these key categories will continue.10 stocks we like better than Eli Lilly › When I last wrote about Eli Lilly (NYSE: LLY) back in September, the shares were only slightly positive for the year. My view at the time was straightforward: This was a st…
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
